clinical trial · NCT07816380
A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Guangzhou JOYO Pharma Co., Ltd·phase3·not yet recruiting·n = 216
NSCLC (Advanced Non-small Cell Lung Cancer)JYP0322 TabletsCrizotinib Capsules
brief summary
This is a randomized, open-label, multicenter phase III study to evaluate the efficacy and safety of JYP0322 compared with crizotinib in previously untreated ROS1-positive locally advanced or metastatic non-small cell lung cancer.
started
Oct 30, 2026
primary completion
Dec 30, 2028
completion
Dec 30, 2029
last updated
Sep 15, 2026
official title
A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol